US nutritional group Abbott has booked a slide in third-quarter sales from its baby-food division thanks to September’s recall of Similac infant formula.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

For the three months to the end of September, sales from Abbott’s pediatric nutritionals division dropped 9.3% to US$679m. For the nine-month period, sales slid 4.5% to $905m.

Last month, Abbott said it would pull millions of containers of its Similac-brand infant formula after beetles were found in its products and in one plant where the product is made.

Overall, however, Abbott said it delivered a “strong” performance in the quarter and confirmed a forecast of double-digit profit growth for the full year.

See Also:

“The strategic actions we’ve taken across our global businesses position us well in high-growth emerging markets as well as promising new therapeutic areas,” said Miles White, chairman and CEO of Abbott.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

For the full earnings statement from Abbott, click here.